TABLE 1.

Antiviral activities of HIV-1 inhibitors in the HIV-1 Rep and HIV-1 RF cell protection assays

InhibitorAntiviral activitya
HIV-1 Rep/MT-2 cellsHIV-1 Rep/PM1 cellsHIV-1 RF cell protection/CEM-SS cells
ClassCompoundEC50 (μM)EC90 (μM)EC50 (μM)EC90 (μM)EC50 (μM)EC90 (μM)
NNRTIEFV0.0013 ± 0.00030.0054 ± 0.00010.0007 ± 0.00040.0048 ± 0.00150.0017 ± 0.00060.0093 ± 0.013
NNRTINVP0.0460.380.0120.260.032 ± 0.0140.097 ± 0.040
NNRTIDLV0.0340.110.00590.100.017 ± 0.0100.036 ± 0.029
PINFV0.021 ± 0.0080.12 ± 0.0520.012 ± 0.0030.055 ± 0.0040.027 ± 0.0170.067 ± 0.044
PISQV0.0120.0260.00530.0340.0059 ± 0.00520.017 ± 0.009
PIIDV0.0260.0550.0120.0470.013 ± 0.0040.038 ± 0.011
NRTIAZT0.034 (0.031, 0.037)0.28 (0.28, 0.27)0.0300.180.010 ± 0.0060.026 ± 0.018
NRTI3TC0.425.50.181.70.080 ± 0.0380.27 ± 0.14
NRTIddl1.714NDND9.8 ± 3.518.8 ± 2.3
NRTId4T0.213.6NDND0.86 (1.2, 0.51)1.6 (2.3, 0.94)
Entry inhibitorATA3.39.9NDND3.8 (4.0, 3.6)24 (40, 7.3)
Tat inhibitorFlavorpiridol0.0360.12NDND0.0480.090
  • a Antiviral activity was determined by measuring induced beta-Gal activity 4 days after HIV-1 NL4-3 infection in the MT-2- or PMI-based HIV-1 Rep assay or by measuring the amount of XTT dye reduction 6 days after infection of CEM-SS cells with HIV-1 RF, as described in Materials and Methods. The results represent the means ± standard deviations (3 to 18 experiments), mean values with individual values in parentheses (2 experiments), or individual values (1 experiment). ND, not determined.